2 Search Results

Decarbonising and digitalising the energy sector requires scalable and interoperable Demand Flexibility (DF) applications. Semantic models are promising technologies for achieving these goals, but existing studies focused on DF applications exhibit limitations. These include dependence on bespoke ontologies, lack of computational methods to generate semantic models, ineffective temporal data management and absence of platforms that use these models to easily develop, configure and deploy controls in real buildings. This paper introduces a semantics-driven framework to enable DF control applications in real buildings. The framework supports the generation of semantic models that adhere to Brick and SAREF while using metadata frommore » Building Information Models (BIM) and Building Automation Systems (BAS). The work also introduces a web platform that leverages these models and an actor and microservices architecture to streamline the development, configuration and deployment of DF controls. The paper demonstrates the framework through a case study, illustrating its ability to integrate diverse data sources, execute DF actuation in a real building, and promote modularity for easy reuse, extension, and customisation of applications. The paper also discusses the alignment between Brick and SAREF, the value of leveraging BIM data sources, and the framework's benefits over existing approaches, demonstrating a 75% reduction in effort for developing, configuring, and deploying building controls.« less

Novel pyridine- and pyrimidine-based allosteric inhibitors are reported that achieve PDE4D subtype selectivity through recognition of a single amino acid difference on a key regulatory domain, known as UCR2, that opens and closes over the catalytic site for cAMP hydrolysis. The design and optimization of lead compounds was based on iterative analysis of X-ray crystal structures combined with metabolite identification. Selectivity for the activated, dimeric form of PDE4D provided potent memory enhancing effects in a mouse model of novel object recognition with improved tolerability and reduced vascular toxicity over earlier PDE4 inhibitors that lack subtype selectivity. The lead compound, 28more » (BPN14770), has entered midstage, human phase 2 clinical trials for the treatment of Fragile X Syndrome.« less